Titre du document / Document title

Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome

Auteur(s) / Author(s)

HEALD A. H. ^{(1 2)} ; KAUSHAL K. ⁽¹⁾ ; SIDDALS K. W. ⁽¹⁾ ; RUDENSKI A. S. ⁽¹⁾ ; ANDERSON S. G. ⁽¹⁾ ; GIBSON J. M. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Diabetes & Endocrinology, University of Manchester, Hope Hospital, Salford, ROYAUME-UNI
⁽²⁾ Department of Medicine, Bishop Auckland Hospital, Co Durham, ROYAUME-UNI

Résumé / Abstract

Aims/hypothesis: IGFs and their binding proteins are increasingly recognised as important in understanding the pathogenesis of cardiovascular disease. Low IGFBP-1, particularly coupled with low IGF-I, is associated with increased cardiovascular risk. In relation to structural and regulatory parallels between IGFBP-1 and - 2 we have now examined the hypothesis that IGFBP-2 may be a marker for cardiovascular risk. Methods: Fasting IGFBP-2, IGFBP-1, IGFBP-3, IGF-I, IGF-II, insulin, C-peptide, glucose, lipids, NEFAs, and HbAlc c were measured in a cohort of 163 patients with type 2 diabetes. Individuals were categorised according to the presence or absence of the metabolic syndrome. Results: Patients with the metabolic syndrome had a lower IGFBP-2 concentration. Low circulating IGFBP-2 was associated with elevated fasting glucose (p = - 0.23, p = 0.003). IGFBP-2 correlated negatively with triglycerides (p=-0.19, p=0.01) and LDL-cholesterol (p = - 0.20, p = 0.01), and positively with insulin sensitivity (HOMA-S) (p = 0.26, p = 0.02). Multivariate logistic regression demonstrated that low IGFBP-2 was independently associated with an increased risk of the metabolic syndrome (OR 0.31 [95% CI 0.11-0.90]; p = 0.03). IGFBP-3 did not differ according to the presence or absence of metabolic syndrome. Conclusion/interpretation: Low IGFBP-2 is associated with multiple cardiovascular risk factors similarly to IGFBP-1. Such associations were not apparent for IGFBP-3. Lack of marked prandial regulation of IGFBP-2, in contradistinction to IGFBP-1, may make IGFBP-2 a more robust biomarker for identification of insulin-resistant individuals at high cardiovascular risk in epidemiological studies.

Revue / Journal Title

Experimental and clinical endocrinology & diabetes   ISSN 0947-7349 

Source / Source

2006, vol. 114, n^o7, pp. 371-376 [6 page(s) (article)] (28 ref.)

Langue / Language

Anglais

Editeur / Publisher

Thieme , Stuttgart, ALLEMAGNE  (1995) (Revue)

Mots-clés anglais / English Keywords

Metabolic diseases ; Endocrinopathy ; Cardiovascular disease ; Insulin-like growth factor binding protein 2 ; Endocrinology ; Cardiovascular disease ; Type 2 diabetes ; Insulin like growth factor binding protein ; Biological marker ; X Syndrome ;

Mots-clés français / French Keywords

Métabolisme pathologie ; Endocrinopathie ; Maladie cardiovasculaire ; Protéine liaison IGFBP2 ; Endocrinologie ; Appareil circulatoire pathologie ; Diabète type 2 ; Protéine liaison IGFBP ; Marqueur biologique ; X Syndrome ;

Mots-clés espagnols / Spanish Keywords

Metabolismo patología ; Endocrinopatía ; Cardiovascular enfermedad ; Proteína enlace IGFBP2 ; Endocrinología ; Aparato circulatorio patología ; Diabetes de tipo 2 ; Proteína enlace IGFBP ; Marcador biológico ; X Síndrome ;

Mots-clés d'auteur / Author Keywords

IGFBP ; metabolic syndrome ; type 2 diabetes ; cardiovascular disease ;

Localisation / Location

INIST-CNRS, Cote INIST : 7404, 35400015696298.0060